Hikmat Abdel-Razeq1,2, Ula Al-Rasheed3, Noor Mashhadani3, Akram Al-Ibraheem3, Rashid Abdel-Razeq4, Shereen Abu Jaradeh5, Razan Mansour6, Rayan Bater6, Shrouq Tbayshat6. 1. Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan. habdelrazeq@khcc.jo. 2. School of Medicine, University of Jordan, Queen Rania Al Abdullah Street, P.O. Box 1269, Amman, 11941, Jordan. habdelrazeq@khcc.jo. 3. Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan. 4. Istishari Hospital, Amman, Jordan. 5. School of Medicine, University of Jordan, Queen Rania Al Abdullah Street, P.O. Box 1269, Amman, 11941, Jordan. 6. Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Abstract
BACKGROUND: Aromatase inhibitors (AI) are the gold standard treatment option for hormone-sensitive postmenopausal women with breast cancer. Several studies had documented the accelerated bone loss associated with AI. AIMS: In this study, we present real-world data describing the efficacy of implementing a comprehensive bone health program to maintain bone mineral density (BMD) in postmenopausal patients with early-stage breast cancer treated with AI. METHODS: A comprehensive bone health program that includes counseling, exercise, nutritional advice, vitamin D supplements and, when needed, intravenous bisphosphonate infusion was implemented following the initiation of endocrine therapy with AI. Postmenopausal women with hormone-sensitive, early-stage breast cancer treated with endocrine therapy using AI were retrospectively identified. All patients had BMD measurements before and at least 1 year after ET initiation. RESULTS: A total of 210 patients were included, median (range) age 67 (43-86) years. At baseline, osteoporosis was documented in 38 (18.1%) and osteopenia in 101 (48.1%) patients. Despite the known negative effect of AI, 32 (84.2%) patients with baseline osteoporosis and 69 (68.3%) of those with osteopenia, had a stable or better BMD. On the other hand, 41 (57.7%) of those with normal baseline BMD had a drop in their follow up BMD, p < 0.001. Vertebral fractures were reported in 3 (11.1%) patients with osteoporosis compared to none in patients with normal BMD, p = 0.021. CONCLUSIONS: Despite the known negative effect of ET on bone health of breast cancer patients, implementing a comprehensive bone health program stabilized or improved BMD.
BACKGROUND: Aromatase inhibitors (AI) are the gold standard treatment option for hormone-sensitive postmenopausal women with breast cancer. Several studies had documented the accelerated bone loss associated with AI. AIMS: In this study, we present real-world data describing the efficacy of implementing a comprehensive bone health program to maintain bone mineral density (BMD) in postmenopausal patients with early-stage breast cancer treated with AI. METHODS: A comprehensive bone health program that includes counseling, exercise, nutritional advice, vitamin D supplements and, when needed, intravenous bisphosphonate infusion was implemented following the initiation of endocrine therapy with AI. Postmenopausal women with hormone-sensitive, early-stage breast cancer treated with endocrine therapy using AI were retrospectively identified. All patients had BMD measurements before and at least 1 year after ET initiation. RESULTS: A total of 210 patients were included, median (range) age 67 (43-86) years. At baseline, osteoporosis was documented in 38 (18.1%) and osteopenia in 101 (48.1%) patients. Despite the known negative effect of AI, 32 (84.2%) patients with baseline osteoporosis and 69 (68.3%) of those with osteopenia, had a stable or better BMD. On the other hand, 41 (57.7%) of those with normal baseline BMD had a drop in their follow up BMD, p < 0.001. Vertebral fractures were reported in 3 (11.1%) patients with osteoporosis compared to none in patients with normal BMD, p = 0.021. CONCLUSIONS: Despite the known negative effect of ET on bone health of breast cancer patients, implementing a comprehensive bone health program stabilized or improved BMD.
Authors: Donald A Berry; Kathleen A Cronin; Sylvia K Plevritis; Dennis G Fryback; Lauren Clarke; Marvin Zelen; Jeanne S Mandelblatt; Andrei Y Yakovlev; J Dik F Habbema; Eric J Feuer Journal: N Engl J Med Date: 2005-10-27 Impact factor: 91.245
Authors: Edith A Perez; Robert G Josse; Kathleen I Pritchard; James N Ingle; Silvana Martino; Brian P Findlay; Tamara N Shenkier; Richard G Tozer; Michael J Palmer; Lois E Shepherd; Shifang Liu; Dongsheng Tu; Paul E Goss Journal: J Clin Oncol Date: 2006-07-05 Impact factor: 44.544
Authors: B Bouvard; J Chatelais; P Soulié; E Hoppé; P Saulnier; O Capitain; M Mege; N Mesgouez-Nebout; E Jadaud; S Abadie-Lacourtoisie; M Campone; E Legrand Journal: Eur J Cancer Date: 2018-07-20 Impact factor: 9.162
Authors: Nigel J Bundred; Ian D Campbell; Neville Davidson; Richard H DeBoer; Holger Eidtmann; Alain Monnier; Patrick Neven; Gunter von Minckwitz; Joel C Miller; Nora L Schenk; Robert E Coleman Journal: Cancer Date: 2008-03-01 Impact factor: 6.860
Authors: Richard Eastell; Judith E Adams; Robert E Coleman; Anthony Howell; Rosemary A Hannon; Jack Cuzick; John R Mackey; Matthias W Beckmann; Glen Clack Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544